- Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's diseaseT Breidert
INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Pitie Salpetriere, Paris, France
J Neurochem 82:615-24. 2002..Since pioglitazone affects primarily the SNpc in our model, different PPARgamma-independent mechanisms may regulate glial activation in the dopaminergic terminals compared with the dopaminergic cell bodies after acute MPTP intoxication...
- The role of glial reaction and inflammation in Parkinson's diseaseE C Hirsch
INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, 75651 Paris Cedex 13, France
Ann N Y Acad Sci 991:214-28. 2003..Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease...